|
1
|
Amedei A, Benagiano M, della Bella C,
Niccolai E and D'Elios MM: Novel immunotherapeutic strategies of
gastric cancer treatment. J Biomed Biotechnol. 2011:4373482011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Vita F, Di Martino N, Fabozzi A,
Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V,
Sforza V, Maranwo L, et al: Clinical management of advanced gastric
cancer: the role of new molecular drugs. World J Gastroenterol.
20:14537–14558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roviello F, Caruso S, Neri A and Marrelli
D: Treatment and prevention of peritoneal carcinomatosis from
gastric cancer by cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy: Overview and rationale. Eur J Surg
Oncol. 39:1309–1316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yk W, Cf G, T Y, Z C, Xw Z, Xx L, Nl M and
Wz Z: Assessment of ERBB2 and EGFR gene amplification and protein
expression in gastric carcinoma by immunohistochemistry and
fluorescence in situ hybridization. Mol Cytogenet. 4:142011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghosh MK, Sharma P, Harbor PC, Rahaman SO
and Haque SJ: PI3K-AKT pathway negatively controls EGFR-dependent
DNA-binding activity of Stat3 in glioblastoma multiforme cells.
Oncogene. 24:7290–7300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu XT, Zhu SN, Xu ZD, Hu XQ, Zhu TF, Chen
JQ and Lu SL: Roles of EGFR-Stat3 signal pathway in carcinogenesis
of experimental hepatoma in rats. J Cancer Res Clin Oncol.
133:145–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mok TS, Lee K and Leung L: Targeting
epidermal growth factor receptor in the management of lung cancer.
Semin Oncol. 41:101–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruzzo A, Graziano F, Canestrari E and
Magnani M: Molecular predictors of efficacy to anti-EGFR agents in
colorectal cancer patients. Curr Cancer Drug Targets. 10:68–79.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang JL, Ren XC and Lin Q: Treating
advanced non-small-cell lung cancer in Chinese patients: Focus on
icotinib. Onco Targets Ther. 7:761–770. 2014.PubMed/NCBI
|
|
11
|
Diasio RB and Fourie J: Targeting the
epidermal growth factor receptor in the treatment of colorectal
cancer: State of the art. Drugs. 66:1441–1463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cappuzzo F, Hirsch FR, Rossi E, Bartolini
S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini
I, et al: Epidermal growth factor receptor gene and protein and
gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer
Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gamboa-Dominguez A, Dominguez-Fonseca C,
Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles
A, Busch R, Hermannstädter C, Nährig J, et al: Epidermal growth
factor receptor expression correlates with poor survival in gastric
adenocarcinoma from Mexican patients: A multivariate analysis using
a standardized immunohistochemical detection system. Mod Pathol.
17:579–587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Yang J, Cai J, Song X, Deng J,
Huang X, Chen D, Yang M, Wery JP, Li S, et al: A subset of gastric
cancers with EGFR amplification and overexpression respond to
cetuximab therapy. Sci Rep. 3:29922013.PubMed/NCBI
|
|
18
|
Kim JG: Molecular targeted therapy for
advanced gastric cancer. Korean J Intern Med. 28:149–155. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Metzger B, Chambeau L, Begon DY, Faber C,
Kayser J, Berchem G, Pauly M, Boniver J, Delvenne P, Dicato M and
Wenner T: The human epidermal growth factor receptor (EGFR) gene in
European patients with advanced colorectal cancer harbors
infrequent mutations in its tyrosine kinase domain. BMC Med Genet.
12:1442011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi
X, Zhang J and Liu T: Analysis of EGFR, HER2, and TOP2A gene status
and chromosomal polysomy in gastric adenocarcinoma from Chinese
patients. BMC Cancer. 8:3632008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Jiang CQ, Guan J, Yang GF, Yue JQ,
Chen HL, Xue JL, Xu ZG, Qian Q and Fan LF: Molecular alterations of
EGFR in small intestinal adenocarcinoma. Int J Colorectal Dis.
28:1329–1335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciardiello F and Tortora G: Epidermal
growth factor receptor (EGFR) as a target in cancer therapy:
Understanding the role of receptor expression and other molecular
determinants that could influence the response to anti-EGFR drugs.
Eur J Cancer. 39:1348–1354. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Castañón E, Martín P, Rolfo C, Fusco JP,
Ceniceros L, Legaspi J, Santisteban M and Gil-Bazo I: Epidermal
Growth Factor Receptor targeting in non-small cell lung cancer:
revisiting different strategies against the same target. Curr Drug
Targets. 15:1273–1283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yarom N and Jonker DJ: The role of the
epidermal growth factor receptor in the mechanism and treatment of
colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
|
|
25
|
Lozano MD, Zulueta JJ, Echeveste JI,
Gúrpide A, Seijo LM, Martín-Algarra S, Del Barrio A, Pio R, Idoate
MA, Labiano T and Perez-Gracia JL: Assessment of epidermal growth
factor receptor and K-ras mutation status in cytological stained
smears of non-small cell lung cancer patients: Correlation with
clinical outcomes. Oncologist. 16:877–885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scartozzi M, Bearzi I, Mandolesi A,
Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F,
Galizia E, et al: Epidermal Growth Factor Receptor (EGFR) gene copy
number (GCN) correlates with clinical activity of
irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a
fluorescence in situ (FISH) and chromogenic in situ hybridization
(CISH) analysis. BMC Cancer. 9:303 View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takehana T, Kunitomo K, Suzuki S, Kono K,
Fujii H, Matsumoto Y and Ooi A: Expression of epidermal growth
factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol.
1:438–445. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Terashima M, Kitada K, Ochiai A, Ichikawa
W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M: ACTS-GC Group: Impact of expression of human epidermal growth
factor receptors EGFR and ERBB2 on survival in stage II/III gastric
cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cappuzzo F, Finocchiaro G, Rossi E, Jänne
PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F,
Pressiani T, et al: EGFR FISH assay predicts for response to
cetuximab in chemotherapy refractory colorectal cancer patients.
Ann Oncol. 19:717–723. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Economou M, Schöni L, Hammer C, Galván JA,
Mueller DE and Zlobec I: Proper paraffin slide storage is crucial
for translational research projects involving immunohistochemistry
stains. Clin Transl Med. 3:42014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown LA and Huntsman D: Fluorescent in
situ hybridization on tissue microarrays: challenges and solutions.
J Mol Histol. 38:151–157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Viana-Pereira M, Lopes JM, Little S,
Milanezi F, Basto D, Pardal F, Jones C and Reis RM: Analysis of
EGFR overexpression, EGFR gene amplification and the EGFRvIII
mutation in Portuguese high-grade gliomas. Anticancer Res.
28:913–920. 2008.PubMed/NCBI
|
|
33
|
Rojo F, Tabernero J, Albanell J, Van
Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Cajal
Ramon YS and Baselga J: Pharmacodynamic studies of gefitinib in
tumor biopsy specimens from patients with advanced gastric
carcinoma. J Clin Oncol. 24:4309–4316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dragovich T, McCoy S, Fenoglio-Preiser CM,
Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS,
Blanke CD and Abbruzzese JL: Phase II trial of erlotinib in
gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J
Clin Oncol. 24:4922–4927. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gancberg D, Di Leo A, Rouas G, Järvinen T,
Verhest A, Isola J, Piccart MJ and Larsimont D: Reliability of the
tissue microarray based FISH for evaluation of the HER-2 oncogene
in breast carcinoma. J Clin Pathol. 55:315–317. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fukuda K, Saikawa Y, Takahashi M,
Takahashi T, Wada N, Kawakubo H, Takeuchi H and Kitagawa Y:
Antitumor effect of cetuximab in combination with S-1 in
EGFR-amplified gastric cancer cells. Int J Oncol. 40:975–982.
2012.PubMed/NCBI
|
